Abstract:This study aims to design and synthesize a novel harmine derivative N-(4-(hydroxycarbamoyl) benzyl)-1-(4-methoxyphenyl)-9H-pyrido [3,4-b]indole-3-carboxamide (HBC) as histone deacetylase (HDAC) inhibitor, and evaluate its antitumor activities and anti-metastasis mechanism. HBC not only exerted significant ant-proliferation activity against five human cancer cell lines, especially for HepG2 cell with an IC50 value of 2.21 μM, which is nearly three-fold lower than SAHA (IC50 = 6.26 µM), but also showed selective HDAC1/6 inhibitory effects in vitro. However, HBC had little effect on normal hepatic cells LO2. Furthermore, HBC simultaneously increased the acetylation of histone H3, H4, and α-tubulin, induced hypochromism by electrostatical interaction with CT-DNA, triggered more significant cancer cell apoptosis and cell cycle arrest at G2/M than SAHA by inhibition of both CDK1 and cyclin B in a concentration dependent manner. In addition, scratch and invasion assay showed that HBC also dose-dependently suppressed migration and invasion capacities of highly metastatic HCC HepG2 cells through down-regulated the expression of tumor metastasis related proteins MMP-2 and MMP-9, significantly better than SAHA. Finally, HBC showed low acute toxicity to mice and significant growth inhibition of the hepatoma tumor in vivo. These results demonstrate that novel harmine-based HDAC inhibitor HBC not only exhibited selective HDAC1/6 inhibitory activity and significant in vitro and in vivo antitumor activity, but also possessed DNA binding effect, apoptosis induction, cell cycle arrest effects, and potent anti-metastasis mechanisms, which may hold great promise as therapeutic agent targeting HDAC1/6 for the intervention of human cancers.

Development of Novel Β-Carboline-based Hydroxamate Derivatives As HDAC Inhibitors with Antiproliferative and Antimetastatic Activities in Human Cancer Cells.

Development of Novel Β-Carboline-based Hydroxamate Derivatives As HDAC Inhibitors with DNA Damage and Apoptosis Inducing Abilities.

Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis

Design and Synthesis of C3‐Substituted Β‐carboline‐based Histone Deacetylase Inhibitors with Potent Antitumor Activities

Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities Against Tumor Growth and Metastasis

A Novel Harmine Derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- Methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), As Histone Deacetylase Inhibitor: in Vitro Antiproliferation, Apoptosis Induction, Cell Cycle Arrest, and Antimetastatic Effects.

Discovery of 1,2,4-Oxadiazole-containing Hydroxamic Acid Derivatives As Histone Deacetylase Inhibitors Potential Application in Cancer Therapy.

Synthesis and Biological Evaluation of Thiophene-Based Hydroxamate Derivatives As HDACis with Antitumor Activities

Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.

Novel Β-Carboline/hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity Via Regulation of the P53 Signaling Pathway

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities

Tetrahydro- β -carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity

Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities

Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors

Development of 3-Hydroxycinnamamide-based HDAC Inhibitors with Potent in Vitro and in Vivo Anti-Tumor Activity

Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities

Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.

Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton

Design, synthesis and mechanism of action of novel 1,9-disubstituted beta-carboline derivatives as antitumor agents

Synthesis, Biological Evaluation and Molecular Docking Studies of 3-(1,3-diphenyl-1h-pyrazol-4-yl)-n-phenylacrylamide Derivatives As Inhibitors of HDAC Activity.

Design, Synthesis, and Biological Evaluation of Novel HDAC/CD13 Dual Inhibitors for the Treatment of Cancer.